3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
28
Melanoma
25
Carcinoma, Renal Cell
22
Lung Neoplasms
11
Neoplasm Metastasis
10
Squamous Cell Carcinoma of Head and Neck
9
Neoplasms
9
Colorectal Neoplasms
9
Prostatic Neoplasms
8
Hodgkin Disease
8
Carcinoma, Transitional Cell
7
Carcinoma, Hepatocellular
7
Adenocarcinoma Of Esophagus
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Rectal Neoplasms
6
Ovarian Neoplasms
6
Pancreatic Neoplasms
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Nasopharyngeal Carcinoma
4
Multiple Myeloma
4
Endometrial Neoplasms
4
Carcinoma, Merkel Cell
4
Carcinoma, Basal Cell
4
Brain Neoplasms
4
Anus Neoplasms
4
Thyroid Neoplasms
3
Sarcoma, Kaposi
3
Recurrence
3
Interventions
belzutifan
2
palbociclib
1
lenvatinib
1
cabozantinib
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
Nivolumab
×
30 days
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled